Compare · ELV vs VCYT
ELV vs VCYT
Side-by-side comparison of Elevance Health Inc. (ELV) and Veracyte Inc. (VCYT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ELV and VCYT operate in Medical Specialities (Health Care), so they compete in similar markets.
- ELV is the larger of the two at $86.82B, about 26.2x VCYT ($3.32B).
- Over the past year, ELV is up 29.3% and VCYT is up 36.6% - VCYT leads by 7.3 points.
- VCYT has been more active in the news (4 items in the past 4 weeks vs 1 for ELV).
- VCYT has more recent analyst coverage (24 ratings vs 23 for ELV).
- Company
- Elevance Health Inc.
- Veracyte Inc.
- Price
- $400.25+0.49%
- $41.27-3.10%
- Market cap
- $86.82B
- $3.32B
- 1M return
- +7.34%
- -30.29%
- 1Y return
- +29.29%
- +36.57%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NYSE
- NASDAQ
- IPO
- 2013
- News (4w)
- 1
- 4
- Recent ratings
- 23
- 24
Elevance Health Inc.
Elevance Health Inc. operates as a health benefits company. It supports consumers, families, and communities across the entire care journey connecting to the care, support, and resources to lead healthier lives. It serves approximately 118 million people through a portfolio of medical, digital, pharmacy, behavioral, clinical, and care solutions. The company was formerly known as Anthem, Inc. and changed its name to Elevance Health Inc. in June 2022. Elevance Health Inc. was founded in 1944 and is headquartered in Indianapolis, Indiana.
Veracyte Inc.
Veracyte, Inc. operates as a genomic diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to identify patients with benign thyroid nodules among those with indeterminate cytopathology results in order to rule out unnecessary thyroid surgery; Percepta Genomic Sequencing Classifier for lung cancer diagnosis; Envisia Genomic Classifier that help physicians to differentiate idiopathic pulmonary fibrosis from other interstitial lung diseases without the need for surgery; and Prosigna Breast Cancer Prognostic Gene Signature Assay test that informs next steps for patients with early-stage breast cancer, as well as provides cancer subtype classification information. It is also developing nasal swab test for early lung cancer detection; Percepta Genomic Atlas for genomic profiling information on small samples of the tumor biopsy; Envisia Classifier, the nCounter analysis system; and LymphMark for lymphoma subtyping test. Veracyte, Inc. has biopharmaceutical collaborations with Johnson & Johnson; Acerta Pharma; Loxo Oncology, Inc.; and Bayer AG. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
Latest ELV
- Elevance Health Strengthens Connected Cancer Care Model to Support Consumers Through Their Health Journey
- Director Peru Ramiro G bought $366,050 worth of shares (1,000 units at $366.05), increasing direct ownership by 10% to 10,908 units (SEC Form 4)
- President and CEO Boudreaux Gail bought $1,002,230 worth of shares (2,725 units at $367.79), increasing direct ownership by 2% to 171,976 units (SEC Form 4)
- SEC Form 10-Q filed by Elevance Health Inc.
- Elevance Health Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Elevance Health Reports Second Quarter 2026 Results; Raises Full-Year Guidance
- Elevance Health to Hold Conference Call and Webcast to Discuss Second Quarter 2026 Results on July 15, 2026
- New Elevance Health Public Policy Institute Study Examines Payment Disputes for Planned Procedures Under the No Surprises Act
- Thomas Carr Howe Middle School Unveils New Fitness and Strength Training Space Through Partnership with Elevance Health and Impact Fitness Foundation
- Elevance Health Makes Clinical Review Faster, More Connected with Health OS
Latest VCYT
- SEC Form 10-Q filed by Veracyte Inc.
- Veracyte Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Veracyte Announces Second Quarter 2026 Financial Results
- Veracyte to Participate in Upcoming Investor Conferences
- Piper Sandler initiated coverage on Veracyte with a new price target
- Veracyte to Release Second Quarter 2026 Financial Results on July 30, 2026
- Director Eastham Karin sold $197,234 worth of shares (3,729 units at $52.89) as part of a pre-agreed trading plan, decreasing direct ownership by 20% to 15,097 units (SEC Form 4)
- SEC Form 144 filed by Veracyte Inc.
- Director Eastham Karin was granted 5,272 shares, increasing direct ownership by 39% to 18,826 units (SEC Form 4)
- Director Jones Evan/ Fa was granted 5,272 shares, increasing direct ownership by 18% to 34,634 units (SEC Form 4)